Cross-reactivity profile for HL60/WT and HL60/TER286
| Drug | WT | TER286 | Resistance Ratios |
|---|---|---|---|
| 10 μM | |||
| TER286 | 9.4 ± 4.3 | 42.8 | 5 |
| TER199 | 22.8 ± 4.3 | 27.0 ± 2.2 | 1 |
| Melphalan | 2.5 ± 0.2 | 6.4 ± 0.8 | 3 |
| 7.0 μM | |||
|---|---|---|---|
| TER286 | 7.5 ± 2.8 | 36.4 ± 5.3 | 5 |
| TER199 | 13.7 ± 1.2 | 14.7 ± 2.8 | 1 |
| Melphalan | 1.3 ± 0.6 | 6.1 ± 2.5 | 5 |
| Taxol1-a | 1.3 ± 0.3 | 1.6 ± 0.2 | 1 |
| Doxorubicin1-a | 7.5 ± 31.0 | 61.3 ± 21.7 | 1 |
| 6.5μM | |||
|---|---|---|---|
| TER286 | 27.4 ± 8.6 | 4 | |
| TER199 | 13.0 ± 1.0 | 1 | |
| Melphalan | 6.2 ± 2.4 | 5 | |
| Taxol1-a | 1.5 ± 0.3 | 1 | |
| Doxorubicin1-a | 56.0 ± 14.0 | 1 | |
| 5.0 μM | |||
| TER286 | 7.0 | 14.5 | 2 |
| TER199 | 22.5 | 27.5 | 1 |
| Melphalan | 1.3 | 3.1 | 2 |
| Taxol1-a | 3.0 | 2.5 | 1 |
| Doxorubicin1-a | 88.3 | 60.3 | 1 |
| Cisplatin | 5.0 | 6.5 | 1 |
| 4.0 μM | |||
| TER286 | 10.3 | 1 | |
| TER199 | 27.5 | 1 | |
| Melphalan | 2.6 | 2 | |
| Taxol1-a | 2.2 | 1 | |
| Doxorubicin1-a | 48.0 | 1 | |
| Cisplatin | 4.5 | 1 |
Cell survival to other classes of chemotherapeutics was assessed 72 h after exposure to the agents. Response was assessed at intermediate steps in the selection process (4–10 μM). IC50 values are shown (μM) except where noted.
↵1-a Indicates nanomolar.